2018

January Updates

  • January 2018:  Alex's Lemonade Stand Foundation has awarded a grant providing 5 years of support for the Childhood Cancer Repository, powered by Alex's Lemonade Stand Foundation that is housed in the TTUHSC Cancer Center (www.CCcells.org). This laboratory, in collaboration with the Children's Oncology Group, establishes, banks, and distributes childhood cancer cell lines and patient-derived xenografts (PDXs) to > 450 laboratories in 21 countries. The outstanding commitment of ALSF to this important repository will insure it continues to be an important resource lab for the COG and for many pediatric oncology investigators world-wide.

2017

December Updates

  • December 2017: C Patrick Reynolds MD PhD and Min Kang PharmD were awarded a $1.6 million grant from the National Cancer Institute entitled Genomic and functional characterization of a panel of neuroblastoma patient-derived xenografts and cell lines. This grant will enable extensive characterization of large panel of neuroblastoma models that are established, banked, and distributed by the Childhood Cancer Repository, which is housed at TTUHSC and is in collaboration with ALSF and COG.

November Updates

  • November 2017: St Baldricks has again awarded to the TTUHSC Cancer Center an infrastructure grant to support conduct of clinical trials in childhood cancer. The grant supports a clinical research associate who is part of the team providing access to clinical trials for children in our region and also making clinical trials of novel agents available to many institutions via the SPOC consortium (www.SPONC.org).

September Updates

June Updates

  • Jun 2017: A paper describing a collaboration between Dr. C Patrick Reynolds and investigators in Australia led by Dr. Roger Reddel was published in Cell Reports. The paper reports that some neuroblastoma cell lines established from patients with progressive disease can proliferate for many generations of cells with no demonstrable mechanism for maintaining telomeres. https://www.ncbi.nlm.nih.gov/pubmed/28636942

April Updates

  • April 2017: TTUHSC Cancer Center faculty member Dr. Barry Maurer was senior author on a paper in Clinical Cancer Research reporting results from a phase I trial of intravenous fenretinide in adults with hematological cancers. The paper documents remarkable activity of intravenous fenretinide in peripheral T cell lymphomas, with multiple sustained complete responses observed. The phase I study led to an ongoing phase II study of intravenous fenretinide in peripheral T cell lymphomas. https://www.ncbi.nlm.nih.gov/pubmed/28420721
  • April 2017: Dr. Monish Makena, who just completed his PhD studies in Dr. Reynolds laboratory published a paper in Molecular Cancer Therapeutics demonstrating synergy in cell culture and enhanced anti-cancer activity from combining the cytotoxic retinoid fenretinide with the histone deacetylase (HDAC) inhibitor romidepsin in lymphoid malignancies, especially in T cell lymphomas and leukemias. This paper informs potential future drug combination clinical trials. https://www.ncbi.nlm.nih.gov/pubmed/27530131


Older News Archives

Placeholder image

Give

Optional subheading text

View more
Placeholder image

Give

Optional subheading text

View more

Got Questions?

We're here to help. Contact us if you have questions.

John Doe

(555) 555 - 5555

john.doe@email.edu

example image

Spotlight Example Header

Enter spotlight text here.